Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Adam Gluskin

Internal Medicine Chicago, IL Medical Doctor

NPI 1154748366 CMS profile 367831

240 E Huron St, McGaw Pavilion, Suite 1-203, Chicago, IL 60611

Open in the dashboard

General payments

$6,884

323 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$7,456

3 holdings reported · through program year 2025

Through program year 2025, Adam Gluskin of Chicago, IL is reported in the CMS Open Payments database as having received $6,884 across 323 general payments and $0 in research payments paid to them. They also declared ownership or investment interests valued at $7,456 across 3 holdings.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 92nd percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

10 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,168 93
2024 General $2,005 98
2023 General $1,560 71
2022 General $582 29
2021 General $476 29
2020 General $29 2
2019 General $65 1
2024 Ownership $3,614 1
2023 Ownership $3,614 1
2022 Ownership $227 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Adam Gluskin
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Adam Gluskin were reported at $2,168. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Adam Gluskin Internal Medicine median Middle half National median
2019 $65 $159 $48–$570 $163
2020 $29 $119 $33–$402 $114
2021 $476 $135 $37–$521 $132
2022 $582 $141 $42–$496 $149
2023 $1,560 $149 $45–$519 $160
2024 $2,005 $154 $47–$537 $164
2025 $2,168 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $1,797 88 payments
  2. Janssen Biotech, Inc. $1,226 50 payments
  3. Takeda Pharmaceuticals U.S.A., Inc. $1,051 54 payments
  4. Salix Pharmaceuticals, a division of Bausch Health US, LLC $535 24 payments
  5. Gilead Sciences, Inc. $392 17 payments
  6. Pfizer Inc. $268 15 payments
  7. Regeneron Healthcare Solutions, Inc. $176 6 payments
  8. QOL Medical, LLC $154 7 payments
  9. Ferring Pharmaceuticals Inc. $153 6 payments
  10. Celltrion USA Inc. $144 6 payments
  11. Other $989 50 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $6,685 320 payments
  2. Education $199 3 payments
Products named General payments · program years 2019–2025
  1. RINVOQ $896 50 payments
  2. ENTYVIO $875 46 payments
  3. STELARA $817 39 payments
  4. LINZESS $484 23 payments
  5. XIFAXAN $438 20 payments
  6. SKYRIZI Immunology $429 23 payments
  7. TREMFYA $409 11 payments
  8. SKYRIZI Immunology $408 21 payments
  9. CREON $376 18 payments
  10. XELJANZ $236 13 payments
  11. Other $2,624 122 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 19 drugs

Part D claims

935

Median for Gastroenterology: 569

Drug cost

$52,279

Median for Gastroenterology: $104,976

Branded share of claims

32.2%

Median for Gastroenterology: 31.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Creon Lipase/Protease/Amylase Brand 11 $19,228
Linzess Linaclotide Brand 16 $12,100
Sod Sulf-Potass Sulf-Mag Sulf Sodium, Potassium,mag Sulfates Brand 77 $5,261
Pantoprazole Sodium Generic 280 $2,796
Gavilyte-C Peg3350/Sod Sulf,bicarb,cl/Kcl Brand 122 $2,180
Lubiprostone Generic 17 $1,803
Sucralfate Generic 38 $1,610
Mesalamine Er Mesalamine Brand 15 $1,343
Budesonide Dr Budesonide Brand 18 $1,108
Rabeprazole Sodium Generic 30 $1,026

The 10 drugs with the highest cost, of 19 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,294 Part D prescribers listed as Gastroenterology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 57 billing codes

Paid by Medicare

$399,271

Of which drugs: $249,366

Medicare patients

674

Average age 75

Services billed

15,795

352 women, 322 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 51%
Ischemic heart disease 45%
Diabetes 37%
Chronic kidney disease 34%
Heart failure 28%
Atrial fibrillation 28%
Depression 26%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, vedolizumab, 1 mg J3380 Office 21 11,103 $193,075
Injection, infliximab, excludes biosimilar, 10 mg J1745 Office 14 1,450 $35,168

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 28 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ENTYVIO
  • Takeda Pharmaceuticals U.S.A., Inc. $307
$307 — 11,103
RINVOQ
  • AbbVie, Inc. $227
$227 — —
STELARA
  • Janssen Biotech, Inc. $172
$172 — —
SKYRIZI
  • AbbVie, Inc. $165
$165 — —
Sucraid
  • QOL Medical, LLC $113
$113 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 28 with Patron

Records

323 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record